also good evidence for the effectiveness of MA as a supportive therapy to ameliorate endocrine therapy-related hot flushes. Trial design: PIONEER is a three-arm, open label, multi-centre randomised phase II pre-surgical window trial evaluating effects of 15 days of preoperative therapy with Letrozole (LET), or LET plus MA 40mg, or LET plus MA 160mg in postmenopausal women with newly diagnosed, ERþ HER2-invasive primary breast cancer. Patients are being recruited in Cambridge, with 5-6 other UK sites due to open in q3/4 2017.
The primary endpoint is % change in proliferation between baseline and day 15 tumour biopsies, measured by Ki67 immunohistochemical (IHC) assessment. Secondary endpoints include: expression of Aurora Kinase A, Caspase 3 and Androgen receptor/PR/ EMT markers by IHC; and safety endpoints. Exploratory endpoints include: transcription factor mapping (ChIP-seq) on paired fresh-frozen tumour samples. Patients are randomised in a 1: 1.5: 1.5 ratio for arms A: B: C. Based on results from previous clinical trials, a mean 66% reduction in Ki67 is anticipated for LET alone (arm A), and a 77.5% reduction for combination arms B and C, based on preclinical data. A recruitment total of 189 patients is required. Pioneer will help determine if there is value in conducting a follow-on adjuvant study to investigate the longer term benefit of combining an aromatase inhibitor with MA, and if so, at what dose (40mg vs. 160mg). Background: The cornerstone of luminal breast tumors treatment both in early and advanced settings is endocrine therapy (ET). Although extended adjuvant ET has demonstrated benefit, a significant percentage of patients relapse. In previous studies, the combination of ET with CDK4/6 inhibitors has shown unprecedented efficacy suggesting that inhibition of the cell cycle in combination with ET is a strategy to keep exploring. The efficacy and safety of metronomic VNB have been confirmed in preclinical and clinical studies and it is now considered a multi-mechanisms of action therapy that could offer advantages when combined with other drugs. VENTANA study is a "window-of-opportunity" trial designed to explore whether, similarly to CDK4/6 inhibitors, oral metronomic VNB in combination with endocrine therapy induces a superior antiproliferative effect than ET alone. We hypothesize that the synergistic biological effect of the combined treatment could be an alternative to CDK4/6 inhibitors in the treatment of luminal breast cancer patients. Trial design: Pts are randomized (1:1:1) to receive LET 2.5mg daily, oral VNB 50mg 3 days a week, or the combination. After 3 weeks of treatment, pts undergo surgery. Preand post-treatment (surgical) samples will be analyzed for gene expression. The primary objective is to test if oral metronomic VNB and LET induce a superior antiproliferative effect than either drug alone in pts with early BC defined as Luminal by PAM50. This will be evaluated by the expression of 11 proliferative genes contained in the PAM50 subtype predictor (BIRC5, CCNB1, CDC20, CDCA1, CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS and UBE2C) as surrogate signature biomarker of its anticancer activity. In addition, 560 BC-related gene signatures will also be analyzed. Enrollment started in July 2016 in 10 sites across Spain. 
